190 related articles for article (PubMed ID: 36926116)
21. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
Setola E; Benini S; Righi A; Gamberi G; Carretta E; Ferrari C; Avnet S; Palmerini E; Magagnoli G; Gambarotti M; Lollini PL; Cesari M; Cocchi S; Paioli A; Longhi A; Scotlandi K; Laginestra MA; Donati DM; Baldini N; Ibrahim T
BMC Cancer; 2023 Sep; 23(1):907. PubMed ID: 37752419
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation.
Emori M; Nakahashi N; Takasawa A; Murata K; Murahashi Y; Shimizu J; Tsukahara T; Sugita S; Takada K; Hasegawa T; Osanai M; Iba K
Hum Cell; 2023 Nov; 36(6):2195-2203. PubMed ID: 37454032
[TBL] [Abstract][Full Text] [Related]
23. Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Trovarelli G; Sbaraglia M; Angelini A; Bellan E; Pala E; Belluzzi E; Pozzuoli A; Borga C; Dei Tos AP; Ruggieri P
Clin Orthop Relat Res; 2024 Jan; 482(6):947-56. PubMed ID: 38170705
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of miRNA expression in dedifferentiated and well-differentiated components of dedifferentiated chondrosarcoma.
Karras FS; Schreier J; Körber-Ferl K; Ullmann SR; Franke S; Roessner A; Jechorek D
Pathol Res Pract; 2023 Apr; 244():154414. PubMed ID: 36963273
[TBL] [Abstract][Full Text] [Related]
25. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
26. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
[TBL] [Abstract][Full Text] [Related]
27. Association of
Murnyak B; Huang LE
Cells; 2021 Aug; 10(8):. PubMed ID: 34440884
[TBL] [Abstract][Full Text] [Related]
28. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
[TBL] [Abstract][Full Text] [Related]
29. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
30. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
[TBL] [Abstract][Full Text] [Related]
31. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
32. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.
van Oosterwijk JG; de Jong D; van Ruler MA; Hogendoorn PC; Dijkstra PD; van Rijswijk CS; Machado I; Llombart-Bosch A; Szuhai K; Bovée JV
BMC Cancer; 2012 Aug; 12():375. PubMed ID: 22928481
[TBL] [Abstract][Full Text] [Related]
33. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.
Makise N; Sekimizu M; Konishi E; Motoi T; Kubo T; Ikoma H; Watanabe SI; Okuma T; Hiraoka N; Fukayama M; Kawai A; Ichikawa H; Yoshida A
Mod Pathol; 2019 Mar; 32(3):435-445. PubMed ID: 30291346
[TBL] [Abstract][Full Text] [Related]
34. TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.
Zhang Y; Chen Y; Yang C; Seger N; Hesla AC; Tsagkozis P; Larsson O; Lin Y; Haglund F
Mod Pathol; 2021 Nov; 34(11):2020-2027. PubMed ID: 34108637
[TBL] [Abstract][Full Text] [Related]
35. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
36. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
[TBL] [Abstract][Full Text] [Related]
37. Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy.
Schoedel K; Heim T; Duensing A; Lohse I; Presutti L; Belayneh R; Bhogal S; Singh-Varma A; Chang A; Chandran U; Marker D; Szabo-Rogers H; Weiss K
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254737
[TBL] [Abstract][Full Text] [Related]
38. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
39. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
[TBL] [Abstract][Full Text] [Related]
40. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]